Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8647435 | Multiple Sclerosis and Related Disorders | 2018 | 16 Pages |
Abstract
Biogenic amines are direct mediators of interactions between immune and nervous systems implicated in the pathogenesis of multiple sclerosis (MS). Recently, great attention has been drawn to studying the effects of biogenic amines on Th17-cells, which play one of the central roles in the development of inflammatory lesions in MS. Results of these studies suggest that, depending on the activation of particular receptors, biogenic amines can both enhance and inhibit Th17-cell functions. Based on these data, targeting biogenic amines and their receptors could be explored as a new kind of additional disease-modifying treatment of MS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Mikhail Melnikov, Vladimir Rogovskii, Alexey Boyko, Mikhail Pashenkov,